Epstein Secrets

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Date: Fri, 24 Jul 2015 20:37:24 +0000 Have

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approv

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FD

g more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as h

From: Sultan Bin Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Importance: — High Have you heard of this co

Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approve

ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig

From: jeffrey E. [[email protected]] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayern Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug t

ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig